INVESTIGADORES
MIRANDA Maria Victoria
artículos
Título:
Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies
Autor/es:
TARGOVNIK, ALEXANDRA MARISA; SIMONIN, JORGE ALEJANDRO; MC CALLUM, GREGORIO JUAN; SMITH, IGNACIO; CUCCOVIA WARLET, FRANCO URIEL; NUGNES, MARÍA VICTORIA; MIRANDA, MARÍA VICTORIA; BELAICH, MARIANO NICOLÁS
Revista:
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
Editorial:
SPRINGER
Referencias:
Lugar: Berlin; Año: 2021
ISSN:
0175-7598
Resumen:
Baculoviruses are insect pathogens widely used as biotechnological tools in diferent felds of life sciences and technologies. The particular biology of these entities (biosafety viruses 1; large circular double-stranded DNA genomes, infective per se; generally of narrow host range on insect larvae; many of the latter being pests in agriculture) and the availability of molecular-biology procedures (e.g., genetic engineering to edit their genomes) and cellular resources (availability of cell lines that grow under in vitro culture conditions) have enabled the application of baculoviruses as active ingredients in pest control, as systems for the expression of recombinant proteins (Baculovirus Expression Vector Systems?BEVS) and as viral vectors for gene delivery in mammals or to display antigenic proteins (Baculoviruses applied on mammals?BacMam). Accordingly,BEVS and BacMam technologies have been introduced in academia because of their availability as commercial systems and ease of use and have also reached the human pharmaceutical industry, as incomparable tools in the development of biological products such as diagnostic kits, vaccines, protein therapies, and?though still in the conceptual stage involving animal models?gene therapies. Among all the baculovirus species, the Autographa californica multiple nucleopolyhedrovirus has been the most highly exploited in the above utilities for the human-biotechnology feld. This review highlights the main achievements (in their diferent stages of development) of the use of BEVS and BacMam technologies for the generation ofproducts for infectious and noninfectious human diseases.
